Both tesamorelin and CJC-1295 are growth hormone-releasing hormone (GHRH) analogs: synthetic peptides built to mimic endogenous GHRH and prompt the pituitary to release growth hormone (GH). The mechanism is shared. The regulatory and research contexts are not, and the published literature treats the two compounds very differently.
What the Research Reports About Each Compound
Tesamorelin is a stabilized analog of human GHRH(1-44) with a trans-3-hexenoic acid modification at the N-terminus. Research describes this modification as resisting dipeptidyl peptidase-IV (DPP-IV) degradation and improving stability relative to native GHRH. It is the only GHRH analog with FDA approval, granted in 2010 under the brand name Egrifta for treating HIV-associated lipodystrophy in adults. The clinical studies behind that approval are publicly documented in FDA review records. Tesamorelin is not approved for anything beyond that one indication.
CJC-1295 is a synthetic GHRH analog that the literature describes in two forms: one without a drug affinity complex (DAC) modification, also called modified GRF(1-29), and one with DAC attached. The DAC modification reportedly binds covalently to circulating serum albumin after injection, which substantially extends circulating half-life compared with native GHRH. CJC-1295 has no regulatory approval for human use in any jurisdiction. It is sold for laboratory research purposes only, not for human consumption.
Key Differences
| Feature | Tesamorelin | CJC-1295 |
|---|---|---|
| Regulatory status | FDA-approved (HIV lipodystrophy, 2010) | No approval; research compound only |
| Structural basis | GHRH(1-44) + N-terminal modification | GHRH(1-29) analog; DAC variant extends half-life |
| Half-life profile | Research describes a short plasma half-life, requiring daily dosing in approved protocol | DAC form reported to have a substantially longer half-life (days, per literature) |
| Human clinical data | Yes — published trials supporting FDA approval | Limited; primarily preclinical or small studies |
| Approved indication | HIV-associated lipodystrophy (adults) | None |
| Availability context | Prescription medicine | Research-use supply only |
Research on CJC-1295 sits at an earlier stage than tesamorelin's clinical dataset. Some published papers describe GH and IGF-1 changes in small human cohorts. Those studies do not amount to approval or endorsement of the compound for therapeutic use.
Mechanism and Shared Pharmacology
Both compounds act at the GHRH receptor on pituitary somatotrophs, stimulating pulsatile GH secretion. The literature notes that GHRH analogs of this class preserve the physiological pulsatility of GH release, which sets them apart from direct GH administration. Research also reports that the GH response stays subject to somatostatin tone. In other words, the increase in GH secretion is modulated by the body's own feedback systems rather than running uncapped.
Because both peptides act upstream of GH itself, the downstream effects the literature describes, including changes in IGF-1 levels, are generally treated as indirect and context-dependent. No GHRH analog should be read as a direct substitute for, or equivalent to, recombinant human GH.
Regulatory and Safety Context
Tesamorelin's FDA approval comes with a prescribing label, documented contraindications, and post-marketing obligations, all publicly available through fda.gov. The formulation has changed over time. Manufacturer Theratechnologies reports that the FDA approved Egrifta SV in 2019 and, more recently, EGRIFTA WR (tesamorelin F8) on March 25, 2025. Per the company, that reformulation reduces injection volume and requires only weekly reconstitution while keeping the same HIV-lipodystrophy indication.
CJC-1295, as a research compound, carries none of that regulatory framework. Anyone interested in tesamorelin should consult FDA prescribing information and a licensed healthcare provider. CJC-1295 is not approved for human use, and its safety profile in humans has not been established through the regulatory process.
Sources
- FDA prescribing information and approval records — fda.gov
- Theratechnologies: EGRIFTA WR (tesamorelin F8) FDA approval announcement — theratech.com
- PubMed: GHRH analog literature — pubmed.ncbi.nlm.nih.gov
- NIH: growth hormone axis background — nih.gov
- Bachem: peptide reference compendium — bachem.com
- Finnrick: third-party peptide testing data — finnrick.com
- Peptide Benchmark: vendor and compound research notes — peptidebenchmark.com